Lataa...
A phase I study of LY317615 (enzastaurin) and temozolomide in patients with gliomas (EORTC trial 26054)
We report a phase 1 study to examine the safety and recommended dose of the oral protein kinase C-beta inhibitor (anti-angiogenic) enzastaurin in combination with single-agent temozolomide. The study was conducted in patients with recurrent glioblastoma or newly diagnosed disease that was not treata...
Tallennettuna:
| Päätekijät: | , , , , , , , , , |
|---|---|
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Oxford University Press
2012
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3280806/ https://ncbi.nlm.nih.gov/pubmed/22291006 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nor221 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|